Abeona Therapeutics Inc. (ABEO)

Market Cap	312.90M -6.1%
Revenue (ttm)	14.54M
Net Income	66.14M
EPS	0.91
Shares Out	57.00M
PE Ratio	6.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,516,139
Open	5.60
Previous Close	5.60
Day's Range	5.41 - 5.68
52-Week Range	4.00 - 7.54
Beta	1.34
Analysts	Strong Buy
Price Target	19.57 (+256.47%)
Earnings Date	May 13, 2026

About ABEO

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 19, 1980
• Employees: 226
• Stock Exchange: NASDAQ
• Ticker Symbol: ABEO
• Website: https://www.abeonatherapeutics.com

Analyst Summary

According to 6 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price target is $19.57, which is an increase of 256.47% from the latest price.

Price Target

$19.57

(256.47% upside)

Analyst Consensus: Strong Buy